Stockreport

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Addex Therapeutics Ltd - American Depositary Shares  (ADXN) 
PDF Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerat [Read more]